A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19

A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19

Background: Coronavirus disease 19 (COVID-19) is spreading globally and treatment options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a broad-spectrum antiviral treatment candidate, optimized for inhalation and intranasal administration (UNI91104) was developed....

Full description

Bibliographic Details
Main Authors: Vibeke Backer, Ulf Sjöbring, Jesper Sonne, Anne Weiss, Morten Hostrup, Helle Krogh Johansen, Victoria Becker, David P. Sonne, Torben Balchen, Mads Jellingsø, Morten Otto Alexander Sommer
Format: Article
Language:English
Published: Elsevier 2021-05-01
Series:The Lancet Regional Health. Europe
Online Access:http://www.sciencedirect.com/science/article/pii/S2666776221000612

Internet

http://www.sciencedirect.com/science/article/pii/S2666776221000612

Similar Items